[精品]恶性黑色素瘤的细胞免疫治疗研究进展.doc

《[精品]恶性黑色素瘤的细胞免疫治疗研究进展.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、恶性黑色素瘤的细胞免疫治疗研究进展恶性黑色素瘤的细胞免疫治疗研究进展［摘耍］恶性黑色素瘤是一种恶性程度极高且发病率持续增长的肿瘤，对术后辅助放、化疗不敏感，预后较差。研究发现，恶性黑色素瘤为免疫原性较高的肿瘤，因此，肿瘤生物治疗得到广泛应用，细胞免疫治疗已成为恶性黑色素瘤个体化综合治疗的重要组成部分及研究热点。本文就恶性黑色素瘤的细胞免疫治疗研究进展作一综述。［关键词］恶性黑色素瘤；细胞免疫治疗；研究进展［中图分类号］R730.5［文献标识码］A［文章编号］1674-4721(2014)09(c)-0194-03Researchprogres

2、soncellimmimotherapyofmalignantmelanomaWUYu-1uoHUANGGuan-junCancerPreventionandControlCenter,Affi1iatedZhanjiangCentalPeoplezsHospitaiofGuangdongMedicalCol1ege,Zhanjiang524037,China［Abstract］Malignantmelanomaisamongthemostlethalofthecutaneousneoplasms,andtheincidenceofithas

3、beenrisingoverthepastfewdecadesMalignantmelanomaisnotsensitivetochemotherapyandradiationtherapy,andhasapoorprognosis.Studiesfoundthatmalignantmelanomashowsahighimmimogenicity,therefore,tumorbiologictherapyiswidelyapplicated.Cellimmunotherapyhasbecomeanimportantpartofindivid

4、ualizedlysystematictreatmentandresearchhotspot・Inthispaper,researchprogressoncellimmunotherapyofmalignantmelanomawasreviewed・［Keywords］Malignantmelanoma；Cel1immunotherapy；Researchprogress恶'性黑色素瘤的细胞免疫治疗研究进展吴育罗黄冠军广东医学院附属湛江中心人民医院肿瘤防治中心，广东湛江524037［摘要］恶性黑色素瘤是一种恶性程度极高且发病率持续增长的肿瘤，

5、对术后辅助放、化疗不敏感，预后较差。研究发现，恶性黑色素瘤为免疫原性较高的肿瘤，因此，肿瘤生物治疗得到广泛应用，细胞免疫治疗已成为恶性黑色素瘤个体化综合治疗的重要组成部分及研究热点。本文就恶性黑色素瘤的细胞免疫治疗研究进展作i综述。［关键词］恶性黑色素瘤；细胞免疫治疗；研究进展［屮图分类号］R730.5［文献标识码］A［文章编号］1674-4721(2014)09(c)-0194-03ResearchprogressoncellimmunotherapyofmalignantmelanomaWUYu-luoHUANGGuan-junCance

6、rPreventionandControlCenter,AffiliatedZhanjiangCentalPeople'sHospitalofGuangdongMedicalCollege,Zhanjiang524037,China［Abstract］Malignantmelanomaisamongthemostlethalofthecutaneousneoplasms,andtheincidenceofithasbeenrisingoverthepastfewdecadesMalignantmelanomaisnotsensitivetoc

7、hemotherapyandradiationtherapy,andhasapoorprognosis.Studiesfoundthatmalignantmelanomashowsahighimmunogenicity,therefore,tumorbiologictherapyiswidelyapplicated.Cellimmunotherapyhasbecomeanimportsntpartofindividualizedlysystematictreatmentandresearchhotspot・Inthispaper,resear

8、chprogressoncellimmunotherapyofmalign&ntmelanomawasreviewed.［Keywords］Malignantmel